AriSLA ETS
FONDAZIONE ITALIANA DI RICERCA PER LA SLA
SCLEROSI LATERALE AMIOTROFICA
ENTE DEL TERZO SETTORE

Scientific program

2026 AriSLA CONGRESS

Excellence and synergies in ALS research

MILAN
Hotel Sheraton San Siro
19th·20th
November 2026

WWW.ARISLA.ORG/CONVEGNO-ARISLA-2026

Segreteria organizzativa
LENA GROUP
Your Preferred Partner

Excellence and synergies in ALS reserch

The AriSLA Conference has been awarded the Medal of the President of the Italian Republic.

MEDAGLIA DEL PRESIDENTE DELLA REPUBBLICA

UNDER THE PATRONAGE OF

RegioneLombardia
IL CONSIGLIO

PATROCINIO
Comune di Milano

FNOMCeO
Federazione Nazionale degli Ordini dei Medici Chirurghi e degli Odontoiatri

Sin SOCIETÀ ITALIANA DI NEUROLOGIA

SINS
ITALIAN SOCIETY FOR NEUROSCIENCE

SUPPORTER

IO CORRO CON GIOVANNI

SPEAKERS AND MODERATORS

Anna Ambrosini	Fondazione AriSLA, Milan
Andrea Bandini	Health Science Interdisciplinary Center, Scuola Superiore Sant'Anna, Pisa; Department of Engineering 'Enzo Ferrari', Università degli Studi di Modena e Reggio Emilia, Modena
Manuela Basso	Department of Cellular, Computational and Integrative Biology (CIBIO), Università degli Studi di Trento, Trento
Valentina Bonetto	Research Center for Amyotrophic Lateral Sclerosis (ALS Center), Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan
Lucie Bruijn	Consultant, Neuroscience Research and Development, Cambridge, United Kingdom
Emanuele Buratti	International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste
Laura Calabresi	Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milan
Andrea Calvo	AOU Città della Salute e della Scienza di Torino; Department of Neuroscience 'Rita Levi Montalcini', Università degli Studi di Torino, Turin
Serena Carra	Department of Biomedical, Metabolic and Neural Sciences, Università degli Studi di Modena e Reggio Emilia, Modena
Federica Cerri	Neuromuscular Omnicentre (NEMO), Fondazione Serena Onlus ETS, Milan
Stefania Corti	Department of Pathophysiology and Transplantation, Università degli Studi di Milano; Neuroscience and Mental Health Department, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan
Sandra D'alfonso	Department of Health Sciences, Università del Piemonte Orientale, Novara
Brian Dickie	MND Association, Northampton, United Kingdom
Marta Fumagalli	Department of Pharmaceutical Sciences, Università degli Studi di Milano, Milan
Valeria Gerbino	Fondazione LIFE - Santa Lucia IRCCS, National Research Council (CNR), Rome
Riccarda Granata	Department of Molecular Biotechnology and Health Sciences, Università degli Studi di Torino, Turin
Christian Lunetta	Department of Neurorehabilitation, Istituti Clinici Scientifici Maugeri IRCCS, Milan
Umberto Manera	SC Neurologia 1U, AOU Città della Salute e della Scienza di Torino, Department of Neuroscience 'Rita Levi Montalcini', Università degli Studi di Torino, Turin
Marcello Manfredi	Department of Translational Medicine, Università del Piemonte Orientale, Novara
Paolo Masciocchi	Fondazione AriSLA, Milan
Fulvia Massimelli	AISLA APS, Milan
Carmelo Milioto	Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milan
Lucia Monaco	Fondazione AriSLA, Milan
Giovanni Nardo	Laboratory of Neuromuscular Diseases, Research Center for ALS, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan
Antonio Orlacchio	Department of Medicine and Surgery, Università degli Studi di Perugia, Perugia
Jeroen Pasterkamp	Department of Translational Neuroscience, University Medical Center (UMC) Utrecht Brain Center, Utrecht, The Netherlands
Piera Pasinelli	Jefferson Weinberg ALS Center, Thomas Jefferson University, Philadelphia, PA, USA
Rosanna Piccirillo	Research Center for Amyotrophic Lateral Sclerosis (ALS Center), Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan
Antonia Ratti	Center of Neurobiology, Human Behaviour and Clinical Neuroscience, IRCCS Istituto Auxologico Italiano, Università degli Studi di Milano, Milan
Nilo Riva	Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan
Alessandro Rosa	Department of Molecular Medicine, Sapienza Università di Roma, Rome
Mario Sabatelli	Centro Clinico NeMO, Roma; Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome
David Taylor	ALS Society of Canada, Toronto, Canada
Nicola Ticozzi	IRCCS Istituto Auxologico Italiano; Università degli Studi di Milano, Milan
Tania Zaglia	Department of Biomedical Sciences, Università degli Studi di Padova, Padua

2026 AriSLA Congress

SCIENTIFIC PROGRAM

Thursday November 19th

08.30 09.00	**PARTICIPANTS REGISTRATION**
09.00 09.30	**OPENING OF PROCEEDINGS AND INSTITUTIONAL GREETINGS** **Lucia Monaco,** AriSLA President, Milan Institutions', representatives
09.30 10.00	**LECTIO MAGISTRALIS** **HUMAN IN VITRO MODELS OF NEUROMUSCULAR DISEASE: FROM PATHOGENESIS TO TARGET DISCOVERY** **Jeroen Pasterkamp,** Utrecht (The Netherlands)
10.00 10.45	**GENETIC IN ALS: NEW STRATEGIES FOR GENE IDENTIFICATION** Chair: **Andrea Calvo,** Turin Discussion panel: **Sandra D'Alfonso,** Novara - **Nicola Ticozzi,** Milan - **Antonio Orlacchio,** Perugia
10.45 - 11.15 Coffee Break	
11.15 12.45	**ADVANCING KNOWLEDGE IN ALS PATHOGENESIS AND STRATEGIC DEVELOPMENTS** Chair: **Lucie Bruijn,** Cambridge (United Kingdom) **PART 1: DIALOGUE BETWEEN NERVE AND MUSCLE** Discussion panel: **Giovanni Nardo,** Milan - **Tania Zaglia,** Padua - **Carmelo Milioto,** Milan - **Rosanna Piccirillo,** Milan **PART 2: IDENTIFICATION OF NEW PATHWAYS** Discussion panel: **Marta Fumagalli,** Milan - **Valeria Gerbino,** Rome - **Riccarda Granata,** Turin
12.45 - 14.00 Lunch	
14.00 15.30	**POSTER SESSION - 1** The even-numbered posters will be presented
15.30 16.30	**FOCUS ON TDP-43 AND RNA METABOLISM** Chair: **Antonia Ratti,** Milan Discussion panel: **Valentina Bonetto,** Milan - **Emanuele Buratti,** Trieste - **Serena Carra,** Modena **Alessandro Rosa,** Rome
16.30 17.30	**HOW TO FIND BIOMARKERS IN ALS?** Chair: **Stefania Corti,** Milan Discussion panel: **Manuela Basso,** Trento - **Nilo Riva,** Milan - **Laura Calabresi,** Milan - **Marcello Manfredi,** Novara
17.30 19.00	**POSTER SESSION – 2** + *SPRITZ TIME* The odd-numbered posters will be presented

Friday November 20th

09.00 09.30	**LECTIO MAGISTRALIS** **PROSPECTS ON INTERNATIONAL RESEARCH STRATEGIES** **David Taylor,** ALS Canada, Toronto (Canada)
9.30 10.30	**CLINICAL BIOMARKERS: IMPACT ON PATIENTS** Chairs: **Anna Ambrosini,** Milan Discussion panel: **Andrea Bandini,** Modena - **Federica Cerri,** Milan - **Umberto Manera,** Turin
10.30 - 11.00 Coffee Break	
11.00 12.30	**INNOVATIVE APPROACHES AND PERSONALIZED MEDICINE IN ALS** Chair: **Lucia Monaco,** Milan Discussion panel: **Christian Lunetta,** Milan - **Fulvia Massimelli,** Milan - **Piera Pasinelli,** Philadelphia (USA) **Mario Sabatelli,** Rome
12.30 13.00	**POSTER PRIZE** Coordinator: **Brian Dickie,** Northampton (UK)
13.00	**NEWLY FUNDED ARISLA GRANTS AND CLOSING REMARKS** **Lucia Monaco,** Milan

THE ACTIVITIES OF THE SECOND DAY WILL BE TRANSMITTED IN STREAMING

AriSLA ETS
FONDAZIONE ITALIANA DI RICERCA PER LA SLA
SCLEROSI LATERALE AMIOTROFICA
ENTE DEL TERZO SETTORE

POSTER

POSTER

P01 A new tunable and conditional mouse model of TDP-43 proteinopathy
C. Marullo, B. Mir, L. Croci, A. Badaloni, L. Nestola, D. Bonanomi, G. Consalez

P02 Addressing the role of Profilin-1pathological mutants in ALS
F. Massaro, S. Arino, G. Fusco, A. De Simone

P03 Advanced Organ-on-Chip (OoC) model for the in vitro study of a familial ALS cluster carrying the G376D mutation in the TARDBP gene
D. Pezzolla, G. Rollo, A. Aprile, J. Rosati, F. Conforti, R. Spataro, V. La Pesa, A. Quattrini, A. Romano, G. Gigli, A. Polini, F. Gervaso

P04 Autophagy-associated signatures in human derived fibroblasts from ALS patients.
F. Ciaiola, R. de Mori, M. Caldarola, G. Vietri, L. Boffa, R. Massa, E. Marchionni, G. Novelli, D. Centonze, A. Spalloni, P. Longone

P05 Beta-aspartyl peptidase activity modulates the TDP43-dependent neurodegeneration.
C. Iaccarino, M. Fais, R. Simula, M. Galioto, A. Lepedda, C. Crosio, L. Sechi

P06 Calcium-driven regulation of Annexin A11 interaction and the Impact of ALS-linked p.D40G mutation.
S. Adinolfi, L. Alfurno, A. Mirabelli, L. Audisio, A. Lago, M. Marengo, S. Oliaro-Bosso, G. Catucci, A. De Simone, F. Spyrakis, F. Dal Piuaz

P07 Characterization of induced Pluripotent Stem Cell (iPSC)-derived microglia from different ALS genetic backgrounds
E. Pellegrini

P08 Corticospinal propagation of full-length TDP-43 toxicity drives brain-to-muscle pathology
J. Marongiu, V. Crippa, I. Marzi, C. Porcedda, M. C. Gagliani, A. Brivio, M. F. Palmas, M. Etzi, M. Serra, K. Aminzadeh, M. A. Casu, I. Mocci, N. Simola, V. Sogos, V. Isola, F. Manchinu, K. Cortese, A. De Simone, F. Chiti, A. Carta

P09 Detection of TDP-43 aggregates and TDP-43 misfolding in olfactory neuroepithelium of patients with ALS.
E. Turano, M. Bongianni, F. Silvestri, E. Bronzato, F. Moda, G. Legname, R. Mariotti, G. Zanusso

P10 Disentangling intron retention from lariat stabilization with Intron Regulation Analyzer (IRA) uncovers an overlooked layer of intronic regulation in sporadic ALS
A. Setti, D. Piccolo, B. Borhy, A. Rosa

P11 Expanding the Genetic and Clinical Spectrum of ALS5/SPG11-Associated Juvenile Amyotrophic Lateral Sclerosis
S. Ramadan, E. Panza, M. Stasi, A. Meyyazhagan, G. Ribas, C. Evangelisti, M. Miele, R. Miyamoto, T. Kawarai, M. França Jr, J. Pedroso, O. Barsottini, H. Teive, A. Orlacchio

P12 Genome wide investigation of oligogenic inheritance in ALS: searching for digenic disease genes with machine learning in a population-based cohort (DIG-ALS)
B. Bartilomo, F. Masoomi Sarvestani, D. Cerotti, F. Caushi, N. Versbraegen, N. Pomella, M. Pennisi, A. Sapienza, M. Lai, S. Vilella, F. De Marchi, S. Zucca, F. De Paoli, M. Grassano, A. Calvo, R. Vasta, U. Manera, C. Moglia, M. Brunetti, L. Corrado, N. Ticozzi, V. Silani, A. Bottrighi, L. Mazzini, T. Lenaerts, A. Ratti, A. Chiò, S. D'Alfonso

P13 Identification of diagnostic and therapeutic ALS targets through cell-type specific analysis of motor nerve damage (IDEALS)
A. Giordano, R. Lombardi, M. Vizziello, T. Domi, L. Pozzi, G. Bath, V. Faltracco, L. Leone, H. Saebfar, E. Dalla Bella, M. Consonni, G. Lauria Pinter, A. Quattrini, D. Bonanomi, N. Riva

P14 Modelling a TARDBP-Family in iPSC-Derived Neural Stem Cells Uncovers Metabolic and Proliferative Defects
E. Vulcano, M. Granata Balduzzi, F. Bovio, E. Perciballi, I. Gargiulo, I. Lombardi, R. Carletti, M. Forcella, J. Rosati, G. Ruotolo, M. Gelati, A. Visioli, P. Fusi, A. Vescovi, D. Ferrari

P15 Native fractionation coupled to high resolution mass spectrometry to detect protein structural alterations in ALS patients' cerebrospinal fluid: the TARCO4ALS project
M. Manfredi, V. De Giorgis, L. Casalino, F. Mohammadinezhad, M. Tortorelli, S. Khoso, C. Comi, L. Tapella, F. De Marchi

P16 NMR fingerprinting of ALS and FTD from the structural polymorphism of TDP-43
L. Cerofolini, B. Susini, C. D'Andrea, E. Guerra, T. Staderini, L. Fiorucci, A. Ciullini, A. Lombardo, I. Dellarole, P. Russomanno, P. Matteini, F. Moda, M. Fragai

P17 NOSRESCUEALS - Unraveling the protective effects of NOS1AP in the rescue of TDP-43 loss of function pathological mechanisms
L. Zangrando, S. Lombardi, R. Klima, L. Braga, E. Buratti

P18 Oxidative stress induces HuD expression by promoting intron splicing: relevance for sporadic ALS (StressHuD Pilot project)
B. Borhy, A. Setti, O. Wilkins, S. Barattucci, M. Chien, A. D'Angelo, D. Piccolo, A. Grosso, E. Eufemi, B. Silvestri, P. Fratta, A. Rosa

P19 VAPB and membrane contact sites in amyotrophic lateral sclerosis pathogenesis
F. Teti, M. Feliziani, L. Iannotta, R. Grassi, D. Pozzi, P. Colombi, M. Leonzino

P20 BIDIRECTIONAL CROSSTALK BETWEEN C2C12 MYOTUBES AND NSC-34 mSOD1 MOTONEURON-LIKE CELLS IN AMYOTROPHIC LATERAL SCLEROSIS
E. Carata, M. Muci, E. Panzarini

P21 CALL 2024 - PG - GHRHagoALS - Protective functions of growth hormone-releasing hormone GHRH agonist MR-409 in amyotrophic lateral sclerosis (ALS)
F. Pedrolli, C. Torazza, I. Gesmundo, T. Bonifacino, R. Schellino, F. La Rocca, G. De Marco, F. Bistolfi, C. Perotti, A. Calvo, W. Sha, M. Wangpaichitr, A. Chiò, M. Boido, A. Ratti, A. Schally, M. Milanese, R. Granata

P22 CRISPR-Cas9-Mediated TBK1 Knockout Reveals Alterations in Protein Aggregation and Mitochondrial Function in Human iPSC-Derived Motor Neurons
F. Manganelli, S. Orsini, I. Salvatori, C. Perfetto, L. Scipioni, O. Carletta, C. Valle, A. Ferri, V. Gerbino

P23 Dissecting neuronal pathology in C9orf72 DPR knock-in mouse models reveals selective, age-dependent spinal motor neurons loss
C. Milioto, M. Cozzi, V. Ferrari, M. Galbiati, A. Poletti, E. Fisher, A. Isaacs

P24 Hampered cholesterol esterification in the cerebrospinal fluid of ALS patients
C. Comi, M. Farè, F. Gerardi, C. Zoia, R. Cusinato, F. Cerri, A. Barbiroli, D. Emide, L. Tremolizzo, L. Calabresi, C. Pavanello

P25 Proteasome and autophagy inhibition reshapes extracellular vesicle cargo and spreads proteotoxicity
E. Casarotto, D. Sproviero, L. Messa, A. Brivio, A. Conti, M. Gagliani, L. Cornaggia, M. Cozzi, M. Chierichetti, V. Marchesi, A. Mohamed, M. Piccolella, V. Ferrari, B. Tedesco, R. Cristofani, P. Rusmini, M. Galbiati, S. Carelli, K. Cortese, F. Chiti, R. Cascella, S. Gagliardi, C. Cereda, A. Poletti, V. Crippa

P26 RILP, a novel TDP-43 interactor and therapeutic target candidate in amyotrophic lateral sclerosis
R. Romano, V. Del Fiore, G. Petito, F. Guerra, G. Girolimetti, M. Calcagnile, G. Ruotolo, S. Tomaselli, J. Rosati, F. Conforti, P. Alifano, R. Senese, C. Bucci

P27 SUMO1 dysregulation in ALS from brain to peripheral compartments
R. Marino, R. Scarcello, A. Corsi, A. Acewicz, T. Stępień, R. Maccarone, M. Feligioni

P28 SUMO2/3 conjugation of TDP-43 protects against aggregation
V. Secco, S. Crotti, E. Verde, M. Morini, F. Antoniani, L. Mediani, E. Buratti, A. Rosa, J. Sterneckert, T. Franzmann, S. Alberti, S. Carra

P29 Targeting a Deubiquitinating Enzyme Attenuates DNA Damage Accumulation in Cellular Models of Amyotrophic Lateral Sclerosis
A. Riccardi, F. Esposito, S. Francia

P30 The MAP1B/TDP-43 Interplay in sporadic ALS: From miRNA-mediated dysregulation to cytoskeletal alterations and phenotypic heterogeneity
F. Dragoni, E. Minucchi, G. Vico, L. Carvetta, L. Diamanti, S. Gagliardi

P31 When muscle communicates: miR-206 drives a pathological muscle-to-autonomic nervous system axis in ALS
T. Zaglia, V. Di Mauro, L. Poli, M. Ronfini, V. Prando, A. Franco-Romero, J. Modica, R. Sartori, M. Albiero, A. Coren, L. Ventura, G. Minervini, G. Sorarù, M. Guescini, A. Musarò, D. Catalucci, M. Mongillo, M. Sandri

P32 A gene therapy approach targeting TDP-43 pathology for ALS (GATTALS)
S. Columbro, S. Scozzari, L. Camporeale, A. Ghioni, M. Tortarolo, P. Fioretti, F. Conci, M. Basso, L. Pasetto, V. Bonetto

P33 Musclin overexpression transiently attenuates muscle and neuromuscular junction pathology in mouse models of ALS
A. Re Cecconi, M. Tortarolo, M. Barone, I. Rubino, F. Palo, P. Fabbrizio, G. Nardo, E. Nikonova, M. Spletter, G. Sorarù, L. Zentilin, C. Bendotti, R. Piccirillo

P34 Expanding the preclinical in vivo platforms to investigate ALS pathomechanisms and therapeutic targets: from the SOD1.G93A rat to C9ORF72 swine models
A. Stanchina, A. Demuro, F. Nucifero, G. Massari, M. Forlani, M. Menna, M. Buora, A. Gazzano, M. Filibian, M. Cattaneo, S. Marcuzzo, C. Corona, F. Lucchini, A. Perota, R. Duchi, V. Bonetto, M. Peviani

P35 Niclosamide attenuates neuroinflammatory, proteostatic and synaptic alterations in a C9orf72-associated ALS/FTD mouse model
M. Milani, D. Boiangiu, S. Amadio, I. Della Valle, P. Fabbrizio, L. Pasetto, G. Proietti, G. Nardo, V. Bonetto, M. Cozzolino, N. D'Ambrosi, S. Apolloni

P36 Satellite cells as determinants of muscle homeostasis in ALS
C. Margotta, P. Fabbrizio, M. Dal Corso, S. Ficara, M. Marangotto, V. Bica, G. Massacci, G. Sorarù, F. Sacco, G. Nardo

P37 Site-directed RNA editing for correcting TARDBP G>A pathogenic mutations
D. Capuano, R. Bossoni, M. Bertoli, L. La Via, S. Santangelo, V. Casarotto, S. Leoni, P. Frugis, M. De Robertis, A. D'Erchia, A. Barbon, A. Ratti, E. Picardi

P38 Bulbar-onset ALS clustering by clinically informed multi-omics (BULB-OMICS)
M. Vizziello, V. Faltracco, L. Maldera, G. Farinazzo, A. De Palma, D. Perico, R. Lombardi, A. Giordano, N. Riva, S. Usai, E. Salvi, S. Marcuzzo, M. Consonni, G. Lauria, P. Mauri, E. Dalla Bella

P39 Circulating Basophils Reveal a Novel Dimension of Immune Dysregulation in Amyotrophic Lateral Sclerosis
D. Raineri, P. Manfredi, S. Nembrini, N. Madonia, F. De Marchi, C. Comi, L. Mazzini, A. Chiocchetti

P40 DORALS (call 2025) - Dysfunctional Oligodendrocytes in ALS: therapeutic targets and sources of new biomarkers
E. Chinosi, S. Raffaele, A. Becchetti, M. Golia, G. D'Arrigo, S. Colombo, C. Torazza, L. Ottoboni, S. Corti, T. Bonifacino, M. Camera, C. Verderio, M. Fumagalli

P41 Cognitive performance in amyotrophic lateral sclerosis (ALS) is dominated by a shared dimension: a data-driven analysis.
C. Karastamati, A. Baj, L. Tavaglione, C. Gattari, N. Madonia, M. Mancani, C. Comi, M. Manfredi, L. Mazzini, G. Tondo, F. De Marchi

P42 Extracellular vesicles in ALS: testing their use as biomarkers for prognosis and disease progression
L. Donini, S. Cabras, E. Matteoni, C. Faccio, G. De Marco, L. Pasetto, M. Favagrossa, A. Ratti, B. Calcagno, F. Verde, A. Canosa, V. Bonetto, R. Dubbioso, R. Zuccarino, R. Tanel, M. Pennuto, N. Riva, J. Mandrioli, G. Sorarù, F. Trojisi, N. Ticozzi, F. Rinaldi, A. Calvo, M. Basso

P43 FLAIR-ALS: Integrating clinical and wearable data to predict respiratory decline in ALS
U. Manera, E. Matteoni, A. Canosa, A. Maccabeo, S. Cabras, F. Palumbo, G. Pellegrino, F. Arcadipane, G. Tabbia, P. Solidoro, A. Chiò, C. Moglia, A. Calvo

P44 Metabolic status and circulating irisin in amyotrophic lateral sclerosis: interim results of the MYOK-ALS study
M. Farè, A. Lizio, F. Gerardi, J. Lops, C. Cattaneo, F. Cerri

P45 PBMC DEG/miRNA Biomarkers of TDP-43 Pathology in ALS
M. Congiu, M. Massidda, G. Borghero, J. Marongiu, I. Marzi, A. Maschio, V. Rallo, M. Serra, C. Porcedda, M. Etzi, M. Palmas, A. Angius, V. Sogos, M. Pateri, M. Steri, V. Coroneo, A. de Simone, G. Cossu, F. Chiti, A. Carta, M. Manchinu

P46 Assessing ALS Preclinical Research Interests in the Italian ALS Community
D. Sproviero, M. Peviani, M. Basso, S. Mannini, M. Feole, C. Milioto, V. Gerbino, T. Petrozziello, R. Schellino, S. Stanga, M. Boido, S. Pozzi, R. Piovesana, G. Merlini, M. Spatafora, P. Cabras, V. Lombardi, S. Gagliardi, E. Grossini, S. Conte, A. Desiderato, N. De Rossi, A. Zicchieri

P47 Italy's first international ALS online seminar series: SLA in Chiaro by Associazione conSLAncio ETS
N. De Rossi

P48 Targeting the pre-symptomatic phase of ALS: development of a prospective natural history and biomarkers study of two Italian clusters carrying mutations in the TARDBP gene.
A. Fasano

SCIENTIFIC SECRETARIAT

Fondazione Italiana di Ricerca per la SLA
Sclerosi Laterale Amiotrofica
Ente del Terzo Settore
via Poerio 14, 20129 Milan
02. 20242390
segreteria@arisla.org
www.arisla.org

AriSLA ETS
FONDAZIONE ITALIANA DI RICERCA PER LA SLA
SCLEROSI LATERALE AMIOTROFICA
ENTE DEL TERZO SETTORE

ORGANIZING SECRETARIAT

Lena Italy S.r.l.
Via Caduti di Marcinelle, 11
20134 Milan
Alberto.calvi@lenagroup.net

LENA GROUP
Your Preferred Partner

With the unconditional sponsorship of:

BRONZE SPONSOR

ITALFARMACO

PARTNER

Biogen

SPONSORS

HOYA
Improve life through vision

DBA
ITALIA